Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued with the launch of new high-dose vials sold at a $150 discount to its auto ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound ... higher-dose vials for the ...

Eli Lilly is proving ... and sales of copycats must stop. Lilly has been faster to find new sales channels, too. In August it began selling low-dose Zepbound vials directly to patients online ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

We came across a bullish thesis on Eli Lilly and Company (LLY ... Mounjaro and Zepbound. These two drugs alone are transforming Lilly’s growth profile and have propelled the company to a ...

As part of the move, Caremark will also drop Eli Lilly's weight loss drug Zepbound from those formularies, which represent tens of millions of patients. Caremark negotiated an undisclosed lower ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

Stream NBC 5 for free, 24/7, wherever you are. As part of the move, Caremark will also drop Eli Lilly's weight loss drug Zepbound from those formularies, which represent tens of millions of patients.

Lilly turned in strong first-quarter results, powered by its GLP-1 weight-loss drugs. But news about its Zepbound drug ... Lilly also introduced higher-dose vials for the self-pay market, and ...